Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aktis OncologyAKTS +3.66%12 3-1 Month Momentum % is 8.93% as of Sep. 02, 2026. GuruFocus rates AKTS with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,386 Biotechnology companies, Aktis Oncology ranks better than 84.2% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-02), Aktis Oncology's 3-1 Month Momentum % is 8.93%.
The industry rank for Aktis Oncology's 3-1 Month Momentum % or its related term are showing as below:
AKTS's 3-1 Month Momentum % is ranked better than 84.2% of 1386
companies
in the Biotechnology industry
Industry Median: -9.25
vs AKTS: 8.93
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Aktis Oncology 3-1 Month Momentum % Related Terms
AKTS vs IMTX, REPL, CGEM: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Aktis Oncology's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aktis Oncology 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aktis Oncology's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Aktis Oncology's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aktis Oncology (AKTS) has a 3-1 Month Momentum % of 8.93% as of Sep. 02, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Aktis Oncology and its competitors. According to the industry distribution chart, Aktis Oncology ranks #219 out of 1386 companies in the Biotechnology industry, placing it in the top 15.8%.
Is Aktis Oncology's 3-1 Month Momentum % too high?
Aktis Oncology's current 3-1 Month Momentum % is 8.93%. Based on the distribution chart, Aktis Oncology ranks #219 out of 1386 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aktis Oncology has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's 3-1 Month Momentum % compare to IMTX and REPL?
According to the Biotechnology industry distribution chart, Aktis Oncology ranks #219 out of 1386 companies for 3-1 Month Momentum %. This places Aktis Oncology in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Aktis Oncology and its competitors. Aktis Oncology's current 3-1 Month Momentum % is 8.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current 3-1 Month Momentum % of 8.93%. The current 3-1 Month Momentum % is 8.93%. Aktis Oncology's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current 3-1 Month Momentum % is 8.93% as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
12GF Score
Get the complete analysis for AKTS
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AKTS has been successfully added to your 
